

# Harri M Itkonen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4882555/publications.pdf>

Version: 2024-02-01

20  
papers

1,020  
citations

567281

15  
h-index

794594

19  
g-index

21  
all docs

21  
docs citations

21  
times ranked

1758  
citing authors

#	ARTICLE	IF	CITATIONS
1	O-GlcNAc Transferase Integrates Metabolic Pathways to Regulate the Stability of c-MYC in Human Prostate Cancer Cells. <i>Cancer Research</i> , 2013, 73, 5277-5287.	0.9	234
2	Structure-Based Evolution of Low Nanomolar O-GlcNAc Transferase Inhibitors. <i>Journal of the American Chemical Society</i> , 2018, 140, 13542-13545.	13.7	117
3	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. <i>Cell Reports</i> , 2017, 19, 2045-2059.	6.4	99
4	c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks. <i>EBioMedicine</i> , 2017, 18, 83-93.	6.1	96
5	Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism. <i>Oncotarget</i> , 2016, 7, 12464-12476.	1.8	71
6	Lipid degradation promotes prostate cancer cell survival. <i>Oncotarget</i> , 2017, 8, 38264-38275.	1.8	64
7	Androgen-regulated metabolism and biosynthesis in prostate cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, T57-T66.	3.1	61
8	High OGT activity is essential for MYC-driven proliferation of prostate cancer cells. <i>Theranostics</i> , 2019, 9, 2183-2197.	10.0	58
9	N-Linked Glycosylation Supports Cross-Talk between Receptor Tyrosine Kinases and Androgen Receptor. <i>PLoS ONE</i> , 2013, 8, e65016.	2.5	39
10	Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9. <i>Molecular Cancer Research</i> , 2020, 18, 1512-1521.	3.4	32
11	O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes. <i>Scientific Reports</i> , 2019, 9, 5670.	3.3	23
12	O-GlcNAc Transferase – An Auxiliary Factor or a Full-blown Oncogene?. <i>Molecular Cancer Research</i> , 2021, 19, 555-564.	3.4	23
13	Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells. <i>Scientific Reports</i> , 2020, 10, 16992.	3.3	21
14	Chromatin binding by the androgen receptor in prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2012, 360, 44-51.	3.2	20
15	CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation. <i>Neoplasia</i> , 2019, 21, 713-720.	5.3	18
16	LXR $\beta$ Regulates Hepatic ChREBP $\beta$ Activity and Lipogenesis upon Glucose, but Not Fructose Feeding in Mice. <i>Nutrients</i> , 2017, 9, 678.	4.1	16
17	Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. <i>RNA Biology</i> , 2021, 18, 722-729.	3.1	13
18	O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage. <i>Journal of Biomedical Science</i> , 2022, 29, 13.	7.0	9

#	ARTICLE	IF	CITATIONS
19	Studying N-Linked Glycosylation of Receptor Tyrosine Kinases. <i>Methods in Molecular Biology</i> , 2015, 1233, 103-109.	0.9	4
20	O-GlcNAc transferase maintains metabolic homeostasis in response to CDK9 inhibition. <i>Glycobiology</i> , 0, , .	2.5	1